Drugs / TDM-105795
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05244980 | Feb → Nov 2022 | androgenetic alopecia | Technoderma Medicines Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04913519 | Apr → Dec 2021 | androgenetic alopecia | Technoderma Medicines Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05802173 | Mar → Nov 2023 | androgenetic alopecia | Technoderma Medicines Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDM-105795 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05802173 ↗ |
| Route | Topical | “TDM-105795 topical solution” NCT04913519 ↗ |